Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETC120 for chronic insomnia disorder
ACTRN12619000714189Phase 2Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Aug 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ETC120 in chronic insomnia (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoints: Change in total sleep time and Change in wake after sleep onset. Started Aug 2019; status: completed.
02
Drugs
ETC120
03
Conditions
chronic insomnia
Beyond the preview
Go deeper on ACTRN12619000714189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000714189.